FDA label
What is Veozah used for?
Veozah contains fezolinetant. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “VEOZAH® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Veozah?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Veozah, tablet, film coated
Indications and Usage, quoted from the label by Astellas Pharma US, Inc. (NDA216578). Cross-references to other label sections are left out.
VEOZAH® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Source: DailyMed label, set id cae9f798-24f9-4580-a4fc-e6c710cbda3c, version 8, effective February 26, 2026. NDC 0469-2460, one of 3 listings for this product.
Questions
What is Veozah used for?
The FDA label says: “VEOZAH® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.”
What drug class is Veozah?
FDA lists fezolinetant in the Neurokinin 3 Receptor Antagonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.